VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

COMy 2017 | The ongoing debate for treating multiple myeloma

Xavier Leleu, MD, PhD of Poitiers University Hospital, Poitiers, France discusses the factors that influence the choice of continuous therapy versus fixed duration therapy in patients with multiple myeloma (MM). Dr Leleu explores the feasibility of continuous treatment, with the goal of striking a balance between optimizing the patient’s quality of life, cost efficiency, the development of resistance and evidence-based practice. He also discusses triplet vs doublet regimens and the need to target treatment choices towards specific patient groups whilst prioritizing the patient’s well-being. Recorded at the 2017 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter